Can Johnson & Johnson’s Imbruvica Sales Beat Roche’s Rituxan In Chronic Lymphocytic Leukemia Market By 2021?
Johnson & Johnson’s (NYSE:JNJ) Imbruvica is poised to beat Roche’s top selling drug in the chronic lymphocytic leukemia drugs market over the next few years. This can be attributed to expected competition for Rituxan from biosimilars, given its market exclusivity period ended last year, and it is expected to see a decline in sales.
Chronic lymphocytic leukemia refers to a cancer associated with blood and bone marrow. It is an important market, given there are 61,780 new cases of leukemia this year, of which one-third are for chronic lymphocytic leukemia. Johnson & Johnson’s top selling drug in this therapeutic area is Imbruvica, with sales of $2.6 billion in 2018. Note that Imbruvica was co-developed by Johnson & Johnson and Pharmacyclics, which was acquired by AbbVie in 2015. Currently, Johnson & Johnson and AbbVie share the marketing rights for the drug. In this note we focus on Imbruvica revenues attributable to Johnson & Johnson. Roche’s Rituxan is currently the leader in the chronic lymphocytic leukemia market with sales of over $5.0 billion in 2018. Note that some of the drugs mentioned below could have been approved for multiple disorders, and the sales figures represent the total oncology revenues garnered by the drug.
Imbruvica is protected from any biosimilar competition till 2026, and it could see sales growth in the near term.
Based on our estimates, Imbruvica could add over $4.0 billion to the company’s revenues by 2021. For perspective, this would be around 10% of the company’s 2018 pharmaceuticals revenue and roughly 5% of the company’s total revenue for 2018. In this note we compare Johnson & Johnson’s Imbruvica sales to that of other treatments for chronic lymphocytic leukemia. You can view our interactive dashboard analysis ~ How Big Could Johnson & Johnson’s Revenue From Chronic Lymphocytic Leukemia Drug Imbruvica Be By 2021? ~ for more details.
- What’s Next For Johnson & Johnson Stock After Beating Q1 Earnings?
- Here’s What To Expect From Johnson & Johnson’s Q1
- What’s Next For Johnson & Johnson Stock After A 6% Decline In A Month?
- Is Johnson & Johnson Stock A Better Pick Over AbbVie?
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Johnson & Johnson Stock At $160?
What Does $4 Billion Mean For Johnson & Johnson?
See Our Detailed Analysis On Johnson & Johnson’s Revenues
Roche’s Rituxan Is Currently The Top Selling Chronic Lymphocytic Leukemia Drug, Followed By AbbVie And Johnson & Johnson’s Imbruvica
Related Analysis
- How Does Johnson & Johnson’s Oncology Drugs Portfolio Compare With That of Roche?
- How Is Johnson & Johnson’s Stelara Placed In Crohn’s Disease Drugs Market?
Combined Sales of Chronic Lymphocytic Leukemia Drugs Above Grew From $6.4 Billion In 2014 To $12.2 Billion In 2018. J&J’s Imbruvica’s Share Increased From 3% To 21% During The Same Period, And It Could Grow To 30% Over The Next Few Years
Imbruvica’s Market Exclusivity Period In The U.S. Ends In 2026, While The Leader Rituxan’s Ended Last Year, As Shown Below. With Rituxan Facing Biosimilar Competition, Its Sales Are Expected To Decline Going Forward. In Fact, Roche Could Lose Over $3 Billion In Sales From Its Oncology Drugs Over The Next Couple of Years.
Loss of Market Exclusivity:
- Imbruvica (Johnson & Johnson): 2026
- Gazyva (Roche): 2025
- Vencelxta (AbbVie): 2030
- Rituxan (Roche): Market Exclusivity Period Has Ended
Johnson & Johnson Has A Wide Pharmaceuticals Portfolio, And Imbruvica Could Generate Over 10% of The Company’s Total Pharmaceutical Sales By 2021
What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs
For CFOs and Finance Teams | Product, R&D, and Marketing Teams
Like our charts? Explore example interactive dashboards and create your own.